6月22日，康方生物盘中下跌3.88%，报82.5港元，成交额1.6亿港元，股价逼近52周低点82.85港元。消息面上，公司核心产品依沃西HARMONi-6研究OS阳性结果于6月1日ASCO全体会议公布后，事件驱动型资金持续获利了结，股价较数据公布后高点累计跌幅已近40%。此前公司董事会批准最多2亿港元回购计划及管理层拟增持合计不超过5000万港元未能有效扭转颓势。叠加美方可能限制对中国生物技术投资的传闻扰动，生物科技板块整体承压，行业内科伦博泰生物跌6.3%、信达生物跌4.46%、三生制药跌4.44%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.